Senior Specialist Biomedical Scientist -Haematology

You will be responsible for the day-to-day management of the laboratory, predominantly leading Haematology & Blood Transfusion section, and will take direction from supporting Operational Leads in transforming the delivery of services.The department utilises Winpath LIMS and uses Sysmex equipment in Haematology and Coagulation across all sites. Bio-Rad and Grifols analysers are used in Haemoglobinopathy and Blood Transfusion respectively.

An exciting opportunity has arisen within the NHS East and South East London Pathology Partnership's (ESEL) Haematology Department.We are looking to appoint an experienced Biomedical Scientist with a positive attitude, strong leadership skills and committed to meeting the needs of our patients by participating in a 24-hour Agenda for Change shift system.The successful candidate will be primarily based at Queen Elizabeth Hospital site (QEH) but may be expected to cover and support other ESEL sites depending on service demand., We invite applications from enthusiastic candidates who have completed a relevant MSc or IBMS Special Examination (Fellowship) and who are interested in opportunities for progression and development within our organisation.

The NHS East and South East London Pathology Partnership is an arms-length organisation providing pathology services to Barts Health NHS Trust, Homerton University Hospital NHS Foundation Trust and Lewisham and Greenwich NHS Trust. The Pathology Partnership is hosted by Barts Health.

The Pathology Partnership is based on well-established models for pathology networks, with the Royal London Hospital becoming the main hub laboratory for the network and Essential Service Laboratories (ESL) as a minimum at all other Hospital sites.

Pathology is made up of the following services - Blood Sciences including Haematology, Blood Transfusion and Biochemistry; Infectious Diseases including Microbiology and Virology; Cellular Pathology including Histopathology, non-gynae Cytology and mortuary services; Immunology; Cytogenetics and Molecular Haematology; Immunophenotyping; Clinical Transplantation and Retinoblastoma.

The 2020/21 total operating costs across the Partnership were c. £126m per annum with a workforce establishment of circa. 822 WTE. We strive to live by our WeCare values and are committed to promoting inclusion, where every staff member has a sense of belonging. We value our differences and fully advocate, cultivate and support an inclusive working environment.